About the Alzheimers Disease Session
Alzheimer’s is the most common cause of dementia, accounting for about 60-70% of all cases. The disease usually manifests in older adults, with symptoms worsening over time. Characterized by the accumulation of beta-amyloid plaques and tau tangles in the brain, Alzheimer's disrupts communication between nerve cells, leading to cognitive decline. Early signs may include forgetfulness and difficulty in problem-solving, eventually progressing to disorientation and personality changes. Genetic factors play a role in Alzheimer's, but lifestyle choices such as diet, exercise, and mental stimulation also impact the risk. While there is no cure, various medications can temporarily alleviate symptoms and improve quality of life. Caregiving for individuals with Alzheimer's can be challenging, as the disease affects not only the patient but also their families. Support groups and resources exist to help caregivers navigate the emotional and physical demands. Researchers continue to explore potential treatments and preventive measures, emphasizing the importance of early detection. Public awareness campaigns aim to reduce stigma and promote understanding of Alzheimer's Disease, fostering empathy and support for those affected by this debilitating condition.
Topics Covered in Alzheimers Disease
Beta-amyloid plaques and tau pathology
Early detection and cognitive assessment
Genetic and lifestyle risk factors
Symptomatic treatment and emerging therapies
Caregiver support and family wellbeing
Public awareness and Alzheimer's stigma reduction
Featured Speakers — Alzheimers Disease 2027
Speaker lineup for this track will be announced soon.
Browse all speakers →Recent Research Presented at Alzheimers Disease Sessions
Selected abstracts from this track will be published here.
Related Scientific Sessions at IPHC 2027
Why Attend the Alzheimers Disease Conference 2027
Earn CPD Credit
Sessions are CPD-accredited; certificates issued to every registered delegate within two weeks of the conference.
Present Your Research
Oral and poster slots for original Alzheimers Disease work, reviewed by the scientific committee.
Network Globally
Meet public health researchers, educators, and policy leaders from around the world across three days.
Publish & Get Indexed
Accepted abstracts appear in the indexed conference proceedings with a citable DOI.
Learn from Keynotes
Plenary lectures from leading voices shaping Alzheimers Disease research and practice.
Hybrid Flexibility
Attend in person in Singapore or join virtually — same programme, same certificate.
Join IPHC 2027 for the Alzheimers Disease track
Oral and poster slots for your work — in person in Singapore or online. Not presenting? Attend as a delegate to learn from the field.
Alzheimers Disease Conference 2027 — FAQs
What is the Alzheimers Disease track at IPHC 2027?
The Alzheimers Disease track is a dedicated stream within IPHC 2027 covering the latest research, innovation, and best practice in Alzheimers Disease. It brings together researchers, educators, and practitioners for oral presentations, posters, and discussion.
Who should attend the Alzheimers Disease sessions?
Public health researchers, practitioners, epidemiologists, educators, doctoral students, and policy leaders with an interest in Alzheimers Disease are all welcome — whether presenting or attending.
Can I present my research in the Alzheimers Disease track?
Yes. Submit an abstract for oral or poster presentation. All submissions are peer-reviewed by the scientific committee; accepted abstracts appear in the indexed proceedings.
Is virtual attendance available for Alzheimers Disease sessions?
Yes. IPHC 2027 is a hybrid conference — attend the Alzheimers Disease track in person in Singapore or join live online, with on-demand access afterward.
Join the IPHC 2027 delegation
Singapore · March 15–17, 2027· Hybrid · in-person & virtual
Attend without presenting.
